PM360 2023 Trailblazer Awards App/Digital Solution or Suite Gold Winner Neurocrine Biosciences, Inc. and Level Ex

Discover TD Solution (Neurocrine Biosciences, Inc. and Level Ex)

In a groundbreaking collaboration, Neurocrine Biosciences, Inc., a leading neuroscience-focused biopharmaceutical company, joined forces with Level Ex, the leading medical video game studio, to innovate education for healthcare providers on identification and management of Tardive Dyskinesia (TD). TD, an involuntary movement disorder linked to the prolonged use of antipsychotic medications for mental health conditions, such as bipolar disorder, depression, and schizophrenia, has long remained underdiagnosed. The condition impacts the lives of nearly 600,000 individuals in the U.S., with a staggering 70% remaining undiagnosed.

Recognizing the glaring gap in diagnosis, Neurocrine and Level Ex developed a remarkable educational tool: Discover TD. Through disease state education, Discover TD hopes to improve diagnosis rates. This cloud-based, interactive digital tool can be used by healthcare professionals to elevate their confidence in recognizing, comprehending, and effectively managing TD. Employing sophisticated video game mechanics, Discover TD immerses healthcare professionals in realistic patient scenarios, enabling them to navigate intricate dialogues, conduct examinations, and make diagnosis and treatment decisions. It sharpens their ability to distinguish subtle nuances among drug-induced movement disorders, including TD, that can be indiscernible to the untrained eye.

The visionary Discover TD platform has been deployed within Neurocrine’s Field Medical and Sales teams. The tool is also accessible at https://mind-td.com/discover-td.

Harnessing the technology that drives today’s top video games, Neurocrine hopes to empower healthcare professionals with confidence in their ability to identify and effectively manage TD, thereby transforming patient care and patients’ quality of life.

Ads

You May Also Like

PM360 2019 Trailblazer Awards Interactive Marketing Program Winner Sanofi Genzyme, Regeneron Pharmaceuticals, and MicroMass Communications

Atopic Dermatitis Insider (Sanofi Genzyme and Regeneron Pharmaceuticals, Inc., MicroMass Communications, Inc.) Atopic dermatitis ...

PM360 2023 Trailblazer Awards Patient/Consumer Education Gold Winner Takeda and Snow Companies

Hello Talk Unbranded Educational Program Series (Takeda and Snow Companies) Takeda’s Hematology franchise has ...

ELITE 2023 Strategist Ticia Cawley of ConnectiveRx

Ticia Cawley VP, Client Solutions ConnectiveRx Expanding Access to Specialty Medications In her more ...